

# EXPLORING ASSOCIATIONS OF THE VAGINAL MICROBIOME AND STI CO-INFECTIONS WITH SPONTANEOUS CLEARANCE OF UROGENITAL *CHLAMYDIA TRACHOMATIS*

## Authors:

Carter KA<sup>1</sup>, Brown SE<sup>1,2</sup>, Tuddenham S<sup>3</sup>, Shardell MD<sup>1,2</sup>, Ghanem KG<sup>3</sup>, Ravel J<sup>1,4</sup>, Brotman RM<sup>1,2</sup>

<sup>1</sup>Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA, <sup>2</sup>Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA, <sup>3</sup>Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA, <sup>4</sup>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA

## Background:

Urogenital *Chlamydia trachomatis* (CT) spontaneously clears (without antibiotics) in up to 44% of women between screening and treatment initiation; underlying mechanisms are poorly understood. We investigated relationships of clinical and microbiome characteristics with CT persistence versus spontaneous clearance.

## Methods:

From 1999-2003, the Longitudinal Study of Vaginal Flora followed reproductive-age women every three months for one year. CT screening for asymptomatic participants started after ligase chain reaction became available mid-study; unscreened endocervical swabs were tested after study completion. We identified CT persistence and clearance events between consecutive visits without CT-active antibiotic use, and we characterized the vaginal microbiome by metagenome sequencing at CT-positive index visits in these events. We used mixed-effects logistic regression to estimate associations between exposures at CT-positive visits and CT persistence versus clearance at subsequent visits.

## Results:

This analysis includes 310 persistence and 301 spontaneous clearance events from 425 participants. In univariable models, CT persistence at the following visit was associated with Black race, age  $\leq 25$ , bacterial vaginosis (Nugent score  $\geq 7$ ), prescription of metronidazole/clindamycin, and *Mycoplasma genitalium* co-infection (all  $p < 0.05$ ). CT persistence was also associated with *Candidatus* Lachnocurva vaginae-dominated and *Gardnerella*-dominated vaginal microbiomes, compared to *Lactobacillus crispatus*, *gasseri*, and *jensenii*-dominated microbiomes (all  $p < 0.05$ ). *M. genitalium* co-infection remained significantly associated with persistence when adjusting for race, bacterial vaginosis, and metronidazole/clindamycin prescription (OR=1.72, 95% CI: 1.04-2.82). *Ca. L. vaginae* dominance (OR=4.86, 95% CI: 2.04-11.57) and *Gardnerella* dominance (OR=2.65, 95% CI: 1.32-5.33) remained significantly associated with persistence when adjusting for age, race, and metronidazole/clindamycin prescription. Hormonal contraception, smoking, douching, baseline CT history, and *Neisseria gonorrhoeae* and *Trichomonas vaginalis* co-infections were not associated with CT persistence versus clearance.

## Conclusion:

An optimal vaginal microbiome during CT infection may reduce CT persistence. The association between *M. genitalium* co-infection and CT persistence should be interrogated further as co-infection may uniquely contribute to adverse sequelae.

**Disclosure of Interest Statement:**

ST has been a consultant for Biofire Diagnostics, Roche Molecular Diagnostics, and Luca Biologics; receives royalties from UPTODATE; has received speaker honoraria from Roche Molecular Diagnostics and Medscape; and has received in-kind donation of sexually transmitted infection (STI) test kits to her institution through Hologic. JR is a cofounder of LUCA Biologics, a biotechnology company focusing on translating microbiome research into live biotherapeutic drugs for women's health. RMB has received in-kind donation of STI test kits to her institution through Hologic. All other authors report no potential conflicts.